Table 2 Clinicopathological data of patients with successful follow-up (N = 750).

From: Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease

Gestational type

# Cases

Patient age in years (range/average/median)

Gestational weeks (range/average/ median)

Serum hCG (mIU/ml) at evacuation (range/average/median)

Hydatidiform Moles

CHM

Combined

165

19–50/31.2/30

6–14/8.2/8

5,006–1,240,000/129,954/103,266

Homozygous CHM

138

19–50/31.6/30

6–12/8.2/8

5,006–862,307/119,246/101,217

Heterozygous CHM

27

19–40/29.3/29

6–14/8.3/8

7,938–1,240,000/183,100/105,277

PHM

218

19–48/31.2/31

6–14/9.6/9

4,298–510,000/80,754/58,459

Non-molar gestations

Diploid HA

305

19–45/31.9/31

6–15/8.9/9

1,091–200,000 /45,422/30,624

Trisomies

54

25–44/32.8/33

7–13/9.1/9

2,476–10,4209 /29,490/20,518

Other genotypes

8

28–39/32.1/30

6–9/7.3/7

13,013–52,692/32,976/37,359

  1. CHM complete hydatidiform mole, PHM partial hydatidiform mole, HA hydropic abortus, hCG human chorionic gonadotropin.
Back to article page